Vaidya Sane Ayurved Laboratories Limited · NSE:MADHAVBAUG
Vaidya Sane Ayurved Laboratories — FY2026 Earnings Presentation
46 slides from Vaidya Sane Ayurved Laboratories's earnings presentation, May 17, 2026
Slide 1: Regulation 30 disclosure cover letter to NSE
Date: 17th May 2026 To, Listing Compliance Department, National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai-400051 NSE Symbol: Madhavbaug Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Slide 2: Investor Presentation
Vaidya Sane Ayurved Laboratories Limited Investor Presentation 1
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Vaidya Sane Ayurved Laboratories Limited (the “Company”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in conn
Slide 4: Table of contents
Table of contents 01 02 03 04 05 3 3
Slide 5: Company Overview
COMPANY __ ves _ + OVERVIEW S07)
Slide 6: About Us
About Us Among leading chains of Cardiac care State of Art Fully Equipped Hospitals clinics & Hospitals ▪ Madhavbaug Hospital Khopoli (NABH Accredited) ▪ Unique medical service institution – focus ▪ Madhavbaug Hospital Nagpur on Traditional Medicine ▪ Madhavbaug Vizag Hospital ▪ Strives to reduce In
Slide 7: Vision & Mission
Vision & Mission Vision Mission 2028 / 2030 Bring 5 Crore people under care via: “To make evidence-based 1,000 Clinics Nationwide Ayurveda the first line for lifestyle disease reversal in India and 10 Operational Hospitals beyond.” Quality Access Affordability Outcomes 6
Slide 8: Company Structure
Company Structure F-Health Accelerators Pvt. Ltd. Easy Ayurveda Pvt. Ltd. Aaharshashtra Foodz Pvt. Ltd. 01 (80% Holding) 02 (15% Holding) 03 (100% Holding) ▪ Shareholding Agreement with Dr. ▪ Incorporated a Company with Ms. Ritika ▪ Focus on start-ups that work in the Janardhana V Hebbar Kandhar - 1
Slide 9: Madhavbaug's 360° Care Ecosystem
Madhavbaug's 3600 Care Ecosystem Clinics Hospitals 320+ first-contact centers offering 4 operational facilities (134+ beds) non-invasive diagnostics and for inpatient care and complex case disease reversal management Manufacturing Digital In-house production via Dynamic Madhavbaug MIB Pulse app (100
Slide 10: Journey so far
Journey so far ▪ Completion of first production batch of ▪ Listing of shares on NSE-Emerge madhavshakti Atta at New Factory, of UV ▪ Khopoli Hospital empanelment with SBI Ayurgen Pharma Private Limited General Insurance ▪ Participated in Ayush Medical Value ▪ NABH of Madhavbaug Khopoli Hospital Trav
Slide 11: Experienced Management Team
Experienced Management Team Dr. Rohit Madhav Sane Dr. Vidyut Bipin Garg Chairman & Managing Director Whole Time Director BAMS from Ayurved Mahavidyalay | Founder | MBBS (Medicine and Surgery) PGDM DLP (2 YRS) in Healthcare | 20+ | Preventive cardiology specialist | years experience as Chief Administ
Slide 12: Key Strengths
Key Strengths Unique combination of modern healing methods and ancient natural practices Experienced Leadership with able & well- trained team led by Dr. Rohit Madhav Sane Effective, Non- Invasive & Affordable Treatments to improve overall health of society State of the art in-house manufacturing fa
Slide 13: 12
12
Slide 14: Business Model Three Pillars
Business Model Three Pillars Clinics Hospitals Products ▪ 320+ company-owned & franchise ▪ 4 facilities with 134+ beds operational ▪ Ayurvedic medicines & standardized clinics diet kits ▪ ~77% revenue share from franchise ▪ High-ticket disease reversal cases ▪ In-house manufacturing for quality netw
Slide 15: Three Pillars of Treatment Protocol
Three Pillars of Treatment Protocol PANCHAKARMA Authentic Ayurvedic detoxification procedures tailored to patient profiles DIET MANAGEMENT HERBAL MEDICINES Standardized in-house diet kits formulated Metal-free Ayurvedic herbal formulations per scientific protocol manufactured in-house 3-Month Aggres
Slide 16: Innovative reversal therapies
Innovative reversal therapies Heart Disease Diabetes Blood Pressure Obesity Reversal Reversal Management Management ▪ Cardioprotective Therapy ▪ Comprehensive Diabetic Care ▪ Blood Pressure Management ▪ Obesity Management ▪ Ischemic Reversal Program Program Program Program ▪ CAD Management ▪ Diabete
Slide 17: Revenue Streams & Unit Economics
Revenue Streams & Unit Economics Business Model (FY26) Clinic Revenue Model (FY26) 15.42% 38.05% Clinics ₹ 166.55 Cr Services ₹ 103.17 Cr ₹ 196.91 Cr ₹ 166.55 Cr Enterprise Revenue Hospitals ₹ 30.36 Cr Clinic Revenue Products ₹ 63.38 Cr 61.95% 84.58% Clinic ARPU Disease Reversal Hospital Revenue Fra
Slide 18: Hospital Network – Capacity & Locations
Hospital Network – Capacity & Locations Khopoli Kondhali Vizag Vadodara 45 30 24 35 BEDS BEDS BEDS BEDS Cashless/CGHS Empaneled Empanelment in Progress Empanelment in Progress Empanelment in Progress 1st Hospital in 2006 2nd Hospital in 2012 3rd Hospital in 2023 4th Hospital in 2025 Fully operationa
Slide 19: Hospital Capabilities & Services
Hospital Capabilities & Services Diagnostics Clinical Services Support Services ✓ ECG ✓ HFRT Program ✓ Dietetics ✓ 2D Echo ✓ IRP Program ✓ In-house Pharmacy ✓ Stress Test ✓ CDC Program ✓ Remote Monitoring ✓ CT Angiography ✓ Panchakarma Therapies ✓ Standardized SOPs ✓ Pathology Lab ✓ Inpatient Care ✓
Slide 20: Patient Journey – 12 Month Protocol
Patient Journey – 12 Month Protocol Onboarding Diagnostics Active Therapy Stabilization Reversal Phase 1: Aggressive Phase 2: Conservative MONTHS 4 - 12 ✓ Detailed diagnosis & profiling Maintenance Panchakarma Structured monthly follow-ups ✓ Initial Panchakarma procedures ✓ Aggressive medicine titra
Slide 21: Multidisciplinary Cardiac Care Clinics
Multidisciplinary Cardiac Care Clinics 20
Slide 22: Malaysia – International Expansion via Maxura JV
Malaysia – International Expansion via Maxura JV First international footprint with strategic 70:30 partnership Madhavbaug Maxura Healthcare 70% 30% Clinical IP & Research Local Operations Setup Standardized Protocols Profit-Sharing JV Regulatory Approvals (70:30) Brand Equity & Trust Regional Marke
Slide 23: Urja Neuro Care – Strategic New Vertical
Urja Neuro Care – Strategic New Vertical Expanding therapeutic portfolio into neurological disorders Urja Neuro Care Neurological Disorders Ayurvedic Approach ₹1.8 Cr Investment Specialty Care Pilot Launch FY26 Diversification High-Need Segment Asset-Light Investment Strategic expansion of therapeut
Slide 24: Multidisciplinary Cardiac Care Clinics
Multidisciplinary Cardiac Care Clinics No. of Clinics (Ownershipwise) Average Revenue per Clinic (Rs. in Lacs) Clinic Enterprise Revenue (In Rs. Lacs) No. of Patient - Total Footfall 353 333 52.05 302 320 49.19 8,58,144 42.23 41.23 10,317 249 266 250 9,025 8,564 8,668 196 8,02,697 6,259 6,344 5,887
Slide 25: Subsidiaries – In-house Manufacturing
Subsidiaries – In-house Manufacturing Dynamic Remedies Pvt Ltd UV Ayurgen Pharma Pvt Ltd ✓ Ayurvedic formulations and nutraceuticals ✓ Standardized, metal-free Ayurvedic medicines ✓ Standardized diet kits production ✓ Stringent quality control across formulations ✓ GMP-aligned manufacturing facility
Slide 26: Clinics and Hospitals Across India
Subsidiaries – In-house Manufacturing 320+ Clinics Nationwide Across 14 States & Union Territories Maharashtra 247 Gujarat 23 Karnataka 22 Madhya Pradesh 11 Uttar Pradesh 11 Delhi-NCR 6 Madhavbaug Hospital Khopoli, 4 Operational Hospitals 134 Total Beds Madhavbaug Hospital Kondhali Khopoli: 45 Beds
Slide 27: Empanelment with Insurance Companies & TPAs
Empanelment with Insurance Companies & TPA’S Insurance Companies Third Party Administrators (TPA) More than 30 Insurance companies empaneled with above Third Party Administrators (TPA) each 26
Slide 28: Digital Ecosystem - MIB Pulse App
Digital Ecosystem - Mib Pulse App ▪ It’s a free app which anyone can use from anywhere in case of Medical MIB Pulse App (+100K Downloads) assistance ▪ App gives you full past history of your health ▪ Medical Assistance ✓ Connected Medical Assistance of Doctors to give patients appropriate solution t
Slide 29: Digital Ecosystem – Power Map
Digital Ecosystem – Power Map ▪ Medical analytics service built for Madhavbaug Doctors to help them reverse Chronic cardiac disease of their patients effectively - ▪ Union Minister for Road Transport and Highways Nitin Gadkari inaugurated Madhavbaug's Power MAP on 15th January 2022 ▪ Critical Care ▪
Slide 30: Research based Disease reversal Diet Kits
Research based Disease reversal Diet Kits 29
Slide 31: Industry
Industry —.--— ‘eo ee Wil F @ 3B
Slide 32: India's Non-Communicable Disease (NCD) Challenges
India’s Non - Communicable Disease (NCD) Challenges 68% of all death in India caused by Non – Communicable diseases ▪ Roughly 77 million Diabetes patients in India – Second Highest in the World India estimated to have 44 million Diabetes ▪ Every 2 minutes, someone in India dies from diabetes or its
Slide 33: Higher Stress increasing Diseased Population
Higher Stress increasing Diseased Population Middle Class Population ( In million) 800.0 400.0 153.0 Working Age Population of India 2010 2020 2030 (in million) 665.0 Share of Non-communicable diseases 495.0 574.0 – Causes of death, India, 2000-25 463.0 397.0 66.0% 68.0% 70.0% 71.0% 56.0% 62.0% 46.0
Slide 34: Re-emergence of Traditional Medical Care
Re-emergence of Traditional Medical Care Market size and services offered Notable trends ▪ Indian Ayurvedic Industry expected to reach US$ 9 ▪ Traditional medical sector developing Traditional Knowledge billion by 2022 - Ayurveda medicines - > 90% plant Digital Library to prevent companies from clai
Slide 35: Financial
Financial —-.-— coven oer aed
Slide 36: Management Comments
Management Comments “FY26 has been a year of strong business momentum and strategic expansion for Vaidya Sane Ayurved Laboratories. During the year, we achieved a healthy revenue growth of 18.9% to ₹106.9 crore, driven by sustained patient additions, growing acceptance of Ayurvedic healthcare soluti
Slide 37: Proposed Acquisition: Parasnath Healthcare (OPC) Pvt. Ltd.
Proposed Acquisition : Parasnath Healthcare (OPC) Pvt. Ltd. Expanding Healthcare Capabilities & Strengthening Market Presence Transaction Snapshot Strategic Rationale Target Profile Key deal metrics and terms Business expansion & synergies Parasnath Healthcare overview Acquisition Cost Stake Acquire
Slide 38: Consolidated Half Yearly – Financial Highlights
Consolidated Half Yearly – Financial Highlights Enterprise Collection (Rs. Cr) Revenue (Rs. Cr) 81.27 85.28 75.63 56.96 51.10 49.94 48.23 48.12 41.80 8.04 9.38 11.51 3.29 0.78 0.00 3.21 0.93 0.22 3.79 0.91 0.41 H2 FY25 H1 FY26 H2 FY26 VSAL Clinics & OPD and Mini Clinics Khopoli Hospital Kondhali Hos
Slide 39: Consolidated Financial Highlights – Half Yearly
Consolidated Financial Highlights – Half Yearly Rs. Crore H2 FY26 H2 FY25 Y-o-Y (%) H1 FY26 Income from Operations 56.96 48.12 49.94 Other Operating Income 0.00 0.00 0.00 Total Income 56.96 48.12 18.37% 49.94 ▪ Revenue from operations for H2 FY26 is Raw Materials 10.64 9.86 8.29 Employee Cost 8.58 8
Slide 40: Consolidated Financial Highlights – Yearly
Consolidated Financial Highlights –Yearly Rs. Crore FY26 FY25 Y-o-Y (%) Income from Operations 106.91 89.92 Other Operating Income 0.00 0.00 ▪ Revenue from operations for FY26 is Total Income 106.91 89.92 18.89% 106.91 Crs as against Rs. 89.92 Crs in Raw Materials 18.93 19.07 FY25, YoY Increase of 1
Slide 41: Annual Financial Highlights
Annual Financial Highlights Enterprise Collection (Rs. Cr) Revenue (Rs. Cr) VSAL Clinics & OPD and Mini Clinics Khopoli Hospital Kondhali Hospital Vizag Hospital 106.91 99.17 99.33 166.55 89.92 157.95 149.00 145.55 74.71 23.00 26.42 20.89 7.00 0.00 7.09 0.08 15.346.82 1.04 7.00 1.84 FY23 FY24 FY25 F
Slide 42: Balance Sheet as on 31st March 2026
Balance Sheet as on 31st March 2026 As on 31st As on 31st As on 31st As on 31st Rs. Crore Rs. Crore Mar’ 26 Mar’ 25 Mar’ 26 Mar’ 25 Shareholder’s Funds 71.68 62.55 Non-current assets 60.20 48.32 Share capital 10.52 10.52 Property, Plant & Equipment 21.94 21.45 Other Equity 61.16 52.03 Intangible ass
Slide 43: Key Balance Sheet Ratios
Key Balance Sheet Ratios RoE(%) RoA(%) 8.80% 8.60% 11.94% 12.54% 11.41% 6.94% 9.04% 9.67% 3.60% 2.87% FY22* FY23 FY24 FY25 FY26 FY22* FY23 FY24 FY25 FY26 RoCE(%) 21.32% 20.45% 15.44% 16.95% 5.63% FY22* FY23 FY24 FY25 FY26 * IPO in FY22 to raise Rs. 20.23 crs 42 RoE = Net Profit/Net Worth | RoA = Net
Slide 44: a> B » F @ 3B
a> B » 1 F @ 3B
Slide 45: Way Ahead
Way Ahead Target health insurance companies to empanel our hospitals - reduce financial burden on patients Invest in integrated marketing Reimbursement of Expenses at campaign to improve visibility Clinics for patients through and awareness Insurance Companies Provide Discounted healthcare Setting u
Slide 46: Thank You
For further information, please contact: Ms. Sapna Vaishnav Mr. Amit Sharma / Mr. Rupesh Rege Vaidya Sane Ayurved Laboratories Ltd AdfactorsPR Pvt. Ltd. Tel: +91 7400192238 Tel: +91 98677 26686 /+91 9594918891 Email: cs@Madhavbaug.com Email: amit.sharma@adfactorspr.com Website: www.madhavbaug.org ru
Vaidya Sane Ayurved Laboratories — FY2026 Earnings Presentation on 6ix